Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma

OBJECTIVE: Our study aimed to evaluate the cost-effectiveness of the addition of serplulimab to chemotherapy (cisplatin and fluorouracil) for programmed death-ligand 1 (PD-L1) positive advanced esophageal squamous cell carcinoma (ESCC) as the first-line treatment in China. METHODS: A three-state Mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Hanrui, Li, Jiafeng, Wen, Feng, Su, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654629/
https://www.ncbi.nlm.nih.gov/pubmed/38023250
http://dx.doi.org/10.3389/fonc.2023.1216960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654629/
https://www.ncbi.nlm.nih.gov/pubmed/38023250
http://dx.doi.org/10.3389/fonc.2023.1216960

Ejemplares similares